Claims
- 1. A compound of formula i:
- 2. A compound of claim 1, wherein R is substituted by —N(R1)CONR2R3.
- 3. A compound of claim 1, wherein R is substituted by —N(R4)COR5.
- 4. A compound of claim 1, wherein R is substituted by —N(R1)OCOaryl.
- 5. A compound of claim 1, wherein R is substituted by —NCHCO2R1.
- 6. A compound of claim 1, wherein R is substituted by ═CHCONR1R2.
- 7. A compound of claim 1, wherein R is substituted by ═CHCN.
- 8. A compound of claim 1, wherein R is substituted by ═NNHSO2R6.
- 9. A compound of claim 1, wherein R is substituted by —N(O)═CHR6.
- 10. A compound of claim 1, wherein R is substituted by —OC(O)NR1R7.
- 11. A compound of claim 1, wherein R is substituted by amino(C1-C6)alkylarylCO2—.
- 12. A compound of claim 1, wherein R is substituted by —OC(O)OR8.
- 13. A compound of formula I:
- 14. A compound of formula I:
- 15. A compound of formula I:
- 16. A compound of formula I:
- 17. A compound selected from the group consisting of:
4-(1,4-Dioxaspiro[4.5]decyl)-1,3-benzenediol; (±)-{4-[2,4-Dihydroxyphenyl]cyclohexylidene}acetic acid; (±)-[4-(2,4-Dihydroxyphenyl)cyclohexylidene]acetonitrile; cis-N[4-(2,4-Dihydroxyphenyl)cyclohexyl]-N-hydroxybenzamide; cis-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]benzamide; trans-4-{4-[(Z)benzylidene(oxido)amino]cyclohexyl}-1,3-benzenediol; trans-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]-N-hydroxybenzamide; syn-8-(2,4-Dihydroxyphenyl)-1-oxaspiro[4.5]decan-2-one; cis-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]-N′-phenylurea; trans-Phenyl-4-(2,4-dihydroxyphenyl)cyclohexylcarbamate; cis-N-Benzyl-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]-N′-ethylurea; cis-N-Benzyl-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]propanamide; trans-4-(2,4-Dihydroxyphenyl)cyclohexylphenylcarbamate; trans-Ethyl[({[4-(2,4-dihydroxyphenyl)cyclohexyl]oxy}carbonyl)amino]acetate; trans-4-(2,4-Dihydroxyphenyl)cyclohexyl benzylcarbamate; trans-4-(2,4-Dihydroxyphenyl)cyclohexyl ethyl carbonate; trans-Methyl[({[4-(2,4-dihydroxyphenyl)cyclohexyl]oxy}carbonyl)amino]acetate; trans-4-(2,4-Dihydroxyphenyl)cyclohexyl methyl imidodicarbonate; cis/trans-4-(1-Oxaspiro[2.5]oct-6-yl)-1,3-benzenediol; 4-(4-Methylenecyclohexyl)-1,3-benzenediol; 4-(3-Cyclohexen-1-yl)-1,3-benzenediol; trans-4-(2,4-Dihydroxyphenyl)cyclohexyl (2R)-2-amino-3-phenylpropanoate; Benzyl [4-(2,4-dihydroxyphenyl)cyclohexylidene]acetate; 4-(1,4-Dithiaspiro[4.5]dec-8-yl)-1,3-benzenediol; N′-[4-(2,4-Dihydroxyphenyl)cyclohexylidene]-4-methylbenzenesulfonohydrazide; trans-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]-3-nitrobenzamide; trans-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]-N′-phenylurea; trans-N-[4-(dihydroxyphenyl)cyclohexyl]-2,2,2-trifluoroacetamide; cis-3-cyano-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]-N-hydroxybenzamide; cis-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]-N-hydroxy-4-(trifluoromethyl)benzamide; cis-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]-N-hydroxymethoxybenzamide; (±)-Methyl[4-(2,4-dihydroxyphenyl)cyclohexylidene]acetate; and a pharmaceutically acceptable salt thereof.
- 18. A pharmaceutical composition for lightening skin or reducing the pigmentation of skin in a human, comprising a pharmaceutically acceptable carrier, and a skin-lightening or pigmentation-reducing amount of a compound of formula I:
- 19. A pharmaceutical composition for lightening skin or reducing the pigmentation of skin in a human, comprising a pharmaceutically acceptable carrier, and a skin-lightening or pigmentation-reducing effective amount of a compound of formula I,
- 20. A pharmaceutical composition for lightening skin or reducing the pigmentation of skin in a human, comprising a pharmaceutically acceptable carrier, and a skin-lightening or pigmentation-reducing effective amount of a compound of formula I,
- 21. A pharmaceutical composition for lightening skin or reducing the pigmentation of skin in a human, comprising a pharmaceutically acceptable carrier, and a skin-lightening or pigmentation-reducing effective amount of a compound of formula I,
- 22. A pharmaceutical composition for lightening skin or reducing the pigmentation of skin in a human, comprising a pharmaceutically acceptable carrier, and a skin-lightening or pigmentation-reducing effective amount of a compound of formula I,
- 23. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a skin-lightening or pigmentation-reducing effective amount of a compound selected from the group consisting of:
4-(1,4-Dioxaspiro[4.5]decyl)-1,3-benzenediol; (±)-{4-[2,4-Dihydroxyphenyl]cyclohexylidene}acetic acid; (±)-[4-(2,4-Dihydroxyphenyl)cyclohexylidene]acetonitrile; cis-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]-N-hydroxybenzamide; cis-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]benzamide; trans-4-{4-[(Z)benzylidene(oxido)amino]cyclohexyl}-1,3-benzenediol; trans-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]-N-hydroxybenzamide; syn-8-(2,4-Dihydroxyphenyl)-1-oxaspiro[4.5]decan-2-one; cis-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]-N′-phenylurea; trans-Phenyl-4-(2,4-dihydroxyphenyl)cyclohexylcarbamate; cis-N-Benzyl-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]-N′-ethylurea; cis-N-Benzyl-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]propanamide; trans-4-(2,4-Dihydroxyphenyl)cyclohexylphenylcarbamate; trans-Ethyl[({[4-(2,4-dihydroxyphenyl)cyclohexyl]oxy}carbonyl)amino]acetate; trans-4-(2,4-Dihydroxyphenyl)cyclohexyl benzylcarbamate; trans-4-(2,4-Dihydroxyphenyl)cyclohexyl ethyl carbonate; trans-Methyl[({[4-(2,4-dihydroxyphenyl)cyclohexyl]oxy}carbonyl)amino]acetate; trans-4-(2,4-Dihydroxyphenyl)cyclohexyl methyl imidodicarbonate; cis/trans-4-(1-Oxaspiro[2.5]oct-6-yl)-1,3-benzenediol; 4-(4-Methylenecyclohexyl)-1,3-benzenediol; 4-(3-Cyclohexen-1-yl)-1,3-benzenediol; trans-4-(2,4-Dihydroxyphenyl)cyclohexyl (2R)-2-amino-3-phenylpropanoate; Benzyl [4-(2,4-dihydroxyphenyl)cyclohexylidene]acetate; 4-(1,4-Dithiaspiro[4.5]dec-8-yl)-1,3-benzenediol; N′-[4-(2,4-Dihydroxyphenyl)cyclohexylidene]-4-methylbenzenesulfonohydrazide; trans-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]-3-nitrobenzamide; trans-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]-N′-phenylurea; trans-N-[4-(dihydroxyphenyl)cyclohexyl]-2,2,2-trifluoroacetamide; cis-3-cyano-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]-N-hydroxybenzamide; cis-N[4(2,4-dihydroxyphenyl)cyclohexyl]-N-hydroxy-4-(trifluoromethyl)benzamide; cis-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]-N-hydroxy-4-methoxybenzamide; (±)-Methyl[4-(2,4-dihydroxyphenyl)cyclohexylidene]acetate; and a pharmaceutically acceptable salt thereof.
- 24. A method of lightening skin in a human, comprising administering to said human a skin-lightening or pigmentation-reducing effective amount of a compound of formula I:
- 25. A method of lightening skin in a human, comprising administering to said human a skin-lightening or pigmentation-reducing effective amount of a compound of formula I,
- 26. A method of lightening skin in a human, comprising administering to said human a skin-lightening or pigmentation-reducing effective amount of a compound of formula I,
- 27. A method of lightening skin in a human, comprising administering to said human a skin-lightening or pigmentation-reducing effective amount of a compound of formula I,
- 28. A method of lightening skin in a human, comprising administering to said human a skin-lightening or pigmentation-reducing effective amount of a compound of formula I,
- 29. A method of lightening skin in a human, comprising administering to said human a skin-lightening or pigmentation-reducing effective amount of a compound selected from the group consisting of:
4-(1,4-Dioxaspiro[4.5]decyl)-1,3-benzenediol; (±)-{4-[2,4-Dihydroxyphenyl]cyclohexylidene}acetic acid; (±)-[4-(2,4-Dihydroxyphenyl)cyclohexylidene]acetonitrile; cis-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]-N-hydroxybenzamide; cis-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]benzamide; trans-4-{4-[(Z)benzylidene(oxido)amino]cyclohexyl}-1,3-benzenediol; trans-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]-N-hydroxybenzamide; syn-8-(2,4-Dihydroxyphenyl)-1-oxaspiro[4.5]decan-2-one; cis-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]-N′-phenylurea; trans-Phenyl-4(2,4-dihydroxyphenyl)cyclohexylcarbamate; cis-N-Benzyl-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]-N′-ethylurea; cis-N-Benzyl-N-[4(2,4-dihydroxyphenyl)cyclohexyl]propanamide; trans-4-(2,4-Dihydroxyphenyl)cyclohexylphenylcarbamate; trans-Ethyl[({[4-(2,4-dihydroxyphenyl)cyclohexyl]oxy}carbonyl)amino]acetate; trans-4-(2,4-Dihydroxyphenyl)cyclohexyl benzylcarbamate; trans-4-(2,4-Dihydroxyphenyl)cyclohexyl ethyl carbonate; trans-Methyl[({[4-(2,4-dihydroxyphenyl)cyclohexyl]oxy}carbonyl)amino]acetate; trans-4-(2,4-Dihydroxyphenyl)cyclohexyl methyl imidodicarbonate; cis/trans-4-(1-Oxaspiro[2.5]oct-6-yl)-1,3-benzenediol; 4-(4-Methylenecyclohexyl)-1,3-benzenediol; 4-(3-Cyclohexen-1-yl)-1,3-benzenediol; trans-4-(2,4-Dihydroxyphenyl)cyclohexyl (2R)-2-amino-3-phenylpropanoate; Benzyl [4-(2,4-dihydroxyphenyl)cyclohexylidene]acetate; 4-(1,4-Dithiaspiro[4.5]dec-8-yl)-1,3-benzenediol; N′-[4-(2,4-Dihydroxyphenyl)cyclohexylidene]4-methylbenzenesulfonohydrazide; trans-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]-3-nitrobenzamide; trans-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]-N′-phenylurea; trans-N-[4-(dihydroxyphenyl)cyclohexyl]-2,2,2-trifluoroacetamide; cis-3-cyano-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]-N-hydroxybenzamide; cis-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]-N-hydroxy-4-(trifluoromethyl)benzamide; cis-N-[4-(2,4-dihydroxyphenyl)cyclohexyl]-N-hydroxymethoxybenzamide; (±)-Methyl[4-(2,4-dihydroxyphenyl)cyclohexylidene]acetate; and a pharmaceutically acceptable salt thereof.
Parent Case Info
[0001] This application claims priority from U.S. provisional application Serial No. 60/234,468, filed Sep. 21, 2000, which is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60234468 |
Sep 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09953690 |
Sep 2001 |
US |
Child |
10386878 |
Mar 2003 |
US |